急诊社区起病肺炎应用DRIP评分后抗生素使用与结局
该准实验前后对照研究在4家美国医院急诊社区起病肺炎住院成人中比较ePNa联合DRIP评分(2015年)与ePNa联合HCAP逻辑(2012年)。DRIP评分组广谱抗生素使用显著减少(OR 0.62;95%CI 0.39-0.98;
要点
- 电子计算DRIP评分较HCAP标准更能指导社区起病肺炎的合理广谱抗生素使用。
- 死亡率、住院时间和费用在DRIP评分组无统计学显著改善。
核心结论
- 电子计算DRIP评分较HCAP标准更有效地指导社区起病肺炎的合理广谱抗生素使用。
- DRIP评分对死亡率、住院时间和费用的平均效应无统计学显著性。
研究设计与样本
- 准实验前后对照实施研究,比较ePNa联合DRIP评分(2015年)与ePNa联合HCAP逻辑(2012年)。
- 纳入4家美国医院急诊收治的社区起病肺炎成人住院患者,共分析2169例入院(2012年1122例,2015年1047例)。
- 采用广义线性模型和双重差分法估计DRIP评分对广谱抗生素使用、死亡率、住院时间和费用的平均处理效应,并调整可用患者层面混杂因素。
主要发现
- DRIP评分对死亡率、住院时间和费用的平均效应无统计学显著性。
临床怎么用
- 在急诊社区起病肺炎患者中,可采用电子化DRIP评分辅助判断是否需要广谱抗生素,以减少不必要的广谱抗生素暴露。
- DRIP评分主要有助于优化抗生素选择,不应预期其直接改善死亡率、住院时间或费用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To guide rational antibiotic selection in community-onset pneumonia, we previously derived and validated a novel prediction tool, the Drug-Resistance in Pneumonia (DRIP) score. In 2015, the DRIP score was integrated into an existing electronic pneumonia clinical decision support tool (ePNa). METHODS: We conducted a quasi-experimental, pre-post implementation study of ePNa with DRIP score (2015) vs ePNa with health-care-associated pneumonia (HCAP) logic (2012) in ED patients admitted with community-onset pneumonia to four US hospitals. Using generalized linear models, we used the difference-in-differences method to estimate the average treatment effect on the treated with respect to ePNa with DRIP score on broad-spectrum antibiotic use, mortality, hospital stay, and cost, adjusting for available patient-level confounders. RESULTS: We analyzed 2,169 adult admissions: 1,122 in 2012 and 1,047 in 2015. A drug-resistant pathogen was recovered in 3.2% of patients in 2012 and 2.8% in 2015; inadequate initial empirical antibiotics were prescribed in 1.1% and 0.5%, respectively (P = .12). A broad-spectrum antibiotic was administered in 40.1% of admissions in 2012 and 33.0% in 2015 (P < .001). Vancomycin days of therapy per 1,000 patient days in 2012 were 287.3 compared with 238.8 in 2015 (P < .001). In the primary analysis, the average treatment effect among patients using the DRIP score was a reduction in broad-spectrum antibiotic use (OR, 0.62; 95% CI, 0.39-0.98; P = .039). However, the average effects for ePNa with DRIP on mortality, length of stay, and cost were not statistically significant. CONCLUSIONS: Electronic calculation of the DRIP score was more effective than HCAP criteria for guiding appropriate broad-spectrum antibiotic use in community-onset pneumonia.
引用
- Webb BJ, Sorensen J, Mecham I, et al. Antibiotic Use and Outcomes After Implementation of the Drug Resistance in Pneumonia Score in ED Patients With Community-Onset Pneumonia. Chest. 2019. PMID: 31077649. doi:10.1016/j.chest.2019.04.093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。